Targeted Delivery of Solid Lipid Nanoparticles Decorated with Chitosan-Folic Containing Gummosin to MCF7 Cells and Investigating Their -Anticancer Effects In vivo and In vitro Conditions

This study aimed to prepare a nanocarrier containing Gummosin (GUM) and decorate it with folate-bound chitosan (CS-FA) to investigate the anticancer effects of the formulation in In vitro and In vivo environments. Nanoparticles (GUM-SCF-NPs) were prepared by homogenization and ultrasound and then characterized. Drug encapsulation efficiency and drug release profile were evaluated by the HPLC method and absorption spectrophotometer. Then the cytotoxicity (MTT), pro-apoptotic (molecular analysis, flow cytometry, fluorescent staining), anti-angiogenesis (molecular analysis and CAM test), and anti-tumor (molecular analysis and tumor-bearing mice) effects of nanoparticles were evaluated. Synthesized nanoparticles with 82.2% drug loading released 77.51% of the loaded drug within 10 days. The IC50 value of nanoparticles against cancer cells was higher than that of free gamosin and was reported to be around 60 mu g/mL. Stopping the cells in the SubG1 phase and the results of fluorescent staining along with increased expression of Bax, caspase 3, and decreased expression of Bcl-2 and TNF-alpha showed the pro-apoptotic effects of GUM-SCF-NPs. The antioxidant potential of GUM-SCF-NPs was confirmed by reducing free radicals and their anti-angiogenesis power by reducing vascular factors and the expression of angiogenesis genes. A significant reduction in tumor volume during 19 days of treatment showed the anti-tumor effects of nanoparticles. These results showed the effectiveness of the treatment in In vivo and In vitro environments.